CRIS on Nasdaq
CURIS INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Taysha Gene Therapies, Inc., Alpha Cognition Inc. or TScan Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs100¢$9.4M
Out of $9.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues, net | $9.4M | $10.9M |
| Cost of royalties | $45.0K | $98.0K |
| Research and development | $28.3M | $38.6M |
| General and administrative | $14.0M | $16.8M |
| Total operating expenses | $42.3M | $55.5M |
| Gain on release of liability related to sale of future royalties associated with sale of assets | $27.2M | $0 |
| Loss from operations | -$5.7M | -$44.5M |
| Interest income | $316.0K | $1.8M |
| Expense related to the sale of future royalties | -$2.2M | -$615.0K |
| Total other income (expense) | -$1.9M | $1.2M |
| Net loss per common share, basic (in dollars per share) | -$0.58 | -$6.88 |
| Net loss per common share, diluted (in dollars per share) | -$0.58 | -$6.88 |
| Weighted average common shares, basic (in shares) | 13.2M shares | 6.3M shares |
| Weighted average common shares, diluted (in shares) | 13.2M shares | 6.3M shares |
| Net loss | -$7.6M | -$43.4M |
| Unrealized gain (loss) on marketable securities | $0 | -$229.0K |
| Comprehensive loss | -$7.6M | -$43.6M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-05-31 | 2025-04-30 |
|---|---|---|---|
| Cash and cash equivalents | $5.1M | ||
| Accounts receivable | $0 | ||
| Prepaid expenses and other current assets | $1.9M | ||
| Total current assets | $6.9M | ||
| Property and equipment, net | $62.0K | ||
| Restricted cash, long-term | $544.0K | ||
| Operating lease right-of-use asset | $1.9M | ||
| Other assets | $1.6M | ||
| Goodwill | $9.0M | ||
| Total assets | $20.0M | ||
| Accounts payable | $5.6M | ||
| Accrued liabilities | $7.3M | ||
| Current portion of operating lease liability | $1.2M | ||
| Current portion of liability related to sale of future royalties | $0 | ||
| Total current liabilities | $14.1M | ||
| Long-term operating lease liability | $428.0K | ||
| Liability related to the sale of future royalties, net | $0 | ||
| Total liabilities | $14.5M | ||
| Preferred stock, $0.01 par value 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | $0 | ||
| Common stock, $0.01 par value68,343,750 shares authorized, 12,928,853 shares issued and outstanding at December 31, 2025; 34,171,875 shares authorized, 8,487,818 shares issued and outstanding at December 31, 2024 | $129.0K | ||
| Additional paid-in capital | $1.3B | ||
| Accumulated deficit | -$1.2B | ||
| Total stockholders equity (deficit) | $5.5M | ||
| Total liabilities and stockholders equity (deficit) | $20.0M | ||
| Preferred stock, par value (in dollars per share) | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 5.0M shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.01 | ||
| Common stock, shares authorized (in shares) | 68.3M shares | 68.3M shares | 34.2M shares |
| Common stock, shares issued (in shares) | 12.9M shares | ||
| Common stock, shares outstanding (in shares) | 12.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$7.6M | -$43.4M |
| Depreciation and amortization | $169.0K | $203.0K |
| Non-cash lease expense | $1.3M | $1.3M |
| Stock-based compensation expense | $4.0M | $5.9M |
| Non-cash activity related to the sale of future royalties prior to the sale of Erivedge | $360.0K | $154.0K |
| Gain on release of liability related to sale of future royalties associated with sale of assets | -$27.2M | $0 |
| Amortization of premiums and discounts on investments | $0 | -$16.0K |
| Accounts receivable | -$1.0M | -$555.0K |
| Prepaid expenses and other assets | $1.6M | $139.0K |
| Accounts payable and accrued and other liabilities | $2.5M | -$2.1M |
| Operating lease liability | -$1.3M | -$1.2M |
| Total adjustments | -$19.6M | $3.8M |
| Net cash used in operating activities | -$27.2M | -$39.6M |
| Purchases of investments | $0 | -$18.1M |
| Sales and maturities of investments | $0 | $47.5M |
| Proceeds from the sale of Erivedge | $2.5M | $0 |
| Net cash provided by investing activities | $2.5M | $29.4M |
| Proceeds from issuance of common stock, pre-funded warrants, and common warrants, net of issuance costs | $15.4M | $12.0M |
| Payment of liability of future royalties, net of imputed interest | -$5.6M | -$8.6M |
| Net cash provided by financing activities | $9.8M | $3.4M |
| Net decrease in cash and cash equivalents and restricted cash | -$14.9M | -$6.7M |
| Issuance costs in accounts payable | $328.0K | $50.0K |
| Cash paid for interest | $1.5M | $461.0K |
| Increase in right-of-use assets and operating lease liabilities resulting from lease modification | $0 | -$1.4M |
Recent filings
- Aug 14, 202610-Q
- Aug 13, 2026424B4
- Aug 12, 2026EFFECT
- Aug 10, 2026S-1
- Jul 30, 20268-K
- Jul 17, 2026DRS
- Jul 9, 20264
- Jul 9, 20264
- Jul 9, 20264
- Jul 9, 20264
- Jul 9, 20264
- Jul 9, 20264
- Jul 9, 20264
- Jul 9, 20264
- Jul 2, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCURIS INC filings on SEC EDGAR
- 2SEC EDGARCURIS INC filings on SEC EDGAR
- 3SEC EDGARCURIS INC 10-K for fiscal 2025
- 4SEC EDGARCURIS INC 10-K for fiscal 2019
- 5SEC EDGARCURIS INC 10-K for fiscal 2021
- 6SEC EDGARCURIS INC 10-K for fiscal 2022
- 7SEC EDGARCURIS INC 10-K for fiscal 2023
- 8SEC EDGARCURIS INC 10-Q for fiscal 2026
- 9SEC EDGARCURIS INC 10-Q for fiscal 2026
- 10SEC EDGARCURIS INC 10-K for fiscal 2019
- 11SEC EDGARCURIS INC 10-K for fiscal 2019